CD19 and congenital rubella syndrome: For example, while assays that use only whole blood or PBMCs may well be suitable to identify the CRS risk associated with T cell engaging therapies whose target is expressed on circulating immune cells (e.g. CD19) many new therapies are in development targeting solid tumor antigens where the target is not expressed in peripheral blood.